rilonacept regeneron (previously arcalyst)
regeneron uk limited - rilonacept - cryopyrin Που Συνδέονται Με Περιοδικές Σύνδρομα - Ανοσοκατασταλτικά - rilonacept regeneron ενδείκνυται για τη θεραπεία περιοδικές σύνδρομα που σχετίζονται με την cryopyrin (ΚΑΠΆΚΙΑ) με σοβαρά συμπτώματα, συμπεριλαμβανομένων Οικογενές σύνδρομο κρύο auto-φλεγμονώδεις (fcas) και το σύνδρομο muckle-wells (mws), σε ενήλικες και παιδιά ηλικίας 12 ετών και παλαιότερα.
aregen 10mg/g cream
meda pharmaceuticals s.a., greece - pimecrolimus - ΚΡΕΜΑ - 10mg/g - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ
tamoxifen/regentgm 40mg tab
ΛΑΠΑΦΑΡΜ Α.Ε. - ΔΙΣΚΙΟ - 40mg
tamoxifen/regentgm 10mg tab
ΛΑΠΑΦΑΡΜ Α.Ε. - ΔΙΣΚΙΟ - 10mg
tamoxifen/regentgm 20mg tab
ΛΑΠΑΦΑΡΜ Α.Ε. - ΔΙΣΚΙΟ - 20mg
libtayo
regeneron ireland designated activity company (dac) - cemiplimab - Καρκίνωμα, σκουός κύτταρο - Αντινεοπλασματικοί παράγοντες - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.
oxaliplatin/deltapharma pd.sol.inf 5mg/ml
deltapharma limited, u.k. regent house, 316 beulah hill,, london se19 3hf, - oxaliplatin - pd.sol.inf (ΚΟΝΙΣ ΓΙΑ ΔΙΑΛΥΜΑ ΠΡΟΣ ΕΓΧΥΣΗ) - 5mg/ml - oxaliplatin 5mg - oxaliplatin
irinotecan/deltapharma c/s.sol.in 20mg/ml
deltapharma limited, u.k. regent house, 316 beulah hill,, london se19 3hf, - irinotecan hydrochloride trihydrate - c/s.sol.in (ΠΥΚΝΟ ΔΙΑΛΥΜΑ ΓΙΑ ΠΑΡΑΣΚΕΥΗ ΔΙΑΛΥΜΑΤΟΣ ΠΡΟΣ ΕΓΧΥΣΗ) - 20mg/ml - irinotecan hydrochloride trihydrate 20mg - irinotecan
ridoca 180mg capsule,hard
aenorasis sa (0000009492) 17 trapezountos & a. papandreou street, melissia-athens, 15127 - temozolomide - capsule,hard - 180mg - temozolomide (0085622931) 180mg - temozolomide
ridoca 5mg capsule,hard
aenorasis sa (0000009492) 17 trapezountos & a. papandreou street, melissia-athens, 15127 - temozolomide - capsule,hard - 5mg - temozolomide (0085622931) 5mg - temozolomide